Anti-aging effects of L-arginine

Journal of Advanced Research

Volumn 1, Issue 3, 2010, Pages 169-177

  Gad, Mohamed Z ^a  

^a German University in Cairo   (Egypt)

Author keywords

Anti aging; Clinical pharmacology; L Arginine; Metabolism; Therapeutic use

Indexed keywords

EID: 77956170673     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2010.05.001     Document Type: Review

References (85)

1. Hedin S.G. Eine methods das lysin zu isolieren, nebst einigen Bemerkungen uber das lysatinin. Z Physiol Chem 1895, 21:297-305.
2. Morris S.M. Arginine: beyond protein. Am J Clin Nutr 2006, 83(2):508S-512S.
3. Dhanakoti S.N., Brosnan J.T., Herzberg G.R., Brosnan M.E. Renal arginine synthesis: studies in vitro and in vivo. Am J Physiol 1990, 259(3 Pt 1):E437-E442.
4. Watford M. The urea cycle: a two-compartment system. Essays Biochem 1991, 26:49-58.
5. White M.F. The transport of cationic amino acids across the plasma membrane of mammalian cells. Biochim Biophys Acta 1985, 822(3-4):355-374.
6. Kamada Y., Nagaretani H., Tamura S., Ohama T., Maruyama T., Hiraoka H., et al. Vascular endothelial dysfunction resulting from l-arginine deficiency in a patient with lysinuric protein intolerance. J Clin Invest 2001, 108(5):717-724.
7. Kone B.C., Kuncewicz T., Zhang W., Yu Z.Y. Protein interactions with nitric oxide synthases: controlling the right time, the right place and the right amount of nitric oxide. Am J Physiol Renal Physiol 2003, 285(2):F178-F190.
8. Boger R.H., Bode Boger S.M. The clinical pharmacology of l-arginine. Annu Rev Pharmacol Toxicol 2001, 41:79-99.
9. Maxwell A.J., Anderson B.E., Cooke J.P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBarReg. Vasc Med 2000, 5(1):11-19.
10. Watanabe G., Tomiyama H., Doba N. Effects of oral administration of l-arginine on renal function in patients with heart failure. J Hypertens 2000, 18(2):229-234.
11. Schwartz L. Amelioration of microvascular angina with arginine supplementation. Ann Intern Med 2003, 138(2):160.
12. Wolf A., Zalpour C., Theilmeier G., Wang B.Y., Ma A., Anderson B., et al. Dietary l-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997, 29(3):479-485.
13. Hurson M., Regan M.C., Kirk S.J., Wasserkrug H.L., Barbul A. Metabolic effects of arginine in a healthy elderly population. J Parent Enteral Nutr 1995, 19(3):227-230.
14. Tarry W.C., Makhoul R.G. l-Arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb 1994, 14(6):938-943.
15. Okazaki J., Komori K., Kawasaki K., Eguchi D., Ishida M., Sugimachi K. l-Arginine inhibits smooth muscle cell proliferation of vein graft intimal thickness in hypercholesterolemic rabbits. Cardiovasc Res 1997, 36(3):429-436.
16. Boger R.H., Ron E.S. l-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005, 10(1):14-23.
17. El Mesallamy H.O., Abdel Hamid S.G., Gad M.Z. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by l-arginine intake. Kidney Blood Pres Res 2008, 31(3):189-195.
18. Cooke J.P., Andon N.A., Girerd X.J., Hirsch A.T., Creager M.A. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991, 83(3):1057-1062.
19. Tsao P.S., McEvoy L.M., Drexler H., Butcher E.C., Cooke J.P. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by l-arginine. Circulation 1994, 89(5):2176-2182.
20. Bode Boger S.M., Boger R.H., Kienke S., Bohme M., Phivthong ngam L., Tsikas D., et al. Chronic dietary supplementation with l-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res 1998, 37(3):756-764.
21. Boger R.H., Bode Boger S.M., Kienke S., Stan A.C., Nafe R., Frolich J.C. Dietary l-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 1998, 136(1):67-77.
22. Maxwell A.J., Cooke J.P. Cardiovascular effects of l-arginine. Curr Opin Nephrol Hypertens 1998, 7(1):63-70.
23. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet 1991, 338(8782-8783):1546-1550.
24. Higashi Y., Oshima T., Ono N., Hiraga H., Yoshimura M., Watanabe M., et al. Intravenous administration of l-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995, 80(7):2198-2202.
25. Udvardy M., Posan E., Palatka K., Altorjay I., Harsfalvi J. Effect of l-arginine on in vitro plasmin-generation and fibrinogenolysis. Thromb Res 1997, 87(1):75-82.
26. Walter R., Mark M., Reinhart W.H. Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. Biochem Biophys Res Commun 2000, 269(3):687-691.
27. Brandes R.P., Brandes S., Boger R.H., Bode Boger S.M., Mugge A. l-Arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix. Life Sci 2000, 66(16):1519-1524.
28. Yin W.H., Chen J.W., Tsai C., Chiang M.C., Young M.S., Lin S.J. l-Arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr 2005, 24(6):988-997.
29. Holt L.E., Albanese A.A. Observations on amino acid deficiencies in man. Trans Assoc Am Physicians 1944, 58:143-156.
30. Tanimura J. Studies on arginine in human semen. II. The effects of medication with l-arginine-HCL on male infertility. Bull Osaka Med Sch 1967, 13(2):84-89.
31. Chen J., Wollman Y., Chernichovsky T., Iaina A., Sofer M., Matzkin H. Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 1999, 83(3):269-273.
32. Moody J.A., Vernet D., Laidlaw S., Rajfer J., Gonzalez Cadavid N.F. Effects of long-term oral administration of l-arginine on the rat erectile response. J Urol 1997, 158(3 Pt 1):942-947.
33. Melman A. This month in investigative urology. l-Arginine and penile erection. J Urol 1997, 158(3 Pt 1):686.
34. Zorgniotti A.W., Lizza E.F. Effect of large doses of the nitric oxide precursor, l-arginine, on erectile dysfunction. Int J Impot Res 1994, 6(1):33-35. [Discussion 36].
35. Klotz T., Mathers M.J., Braun M., Bloch W., Engelmann U. Effectiveness of oral l-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999, 63(4):220-223.
36. Toda N., Ayajiki K., Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005, 106(2):233-266.
37. Lopez Belmonte J., Whittle B.J., Moncada S. The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 1993, 108(1):73-78.
38. Calatayud S., Sanz M.J., Canet A., Bello R., de Rojas F.D., Esplugues J.V. Mechanisms of gastroprotection by transdermal nitroglycerin in the rat. Br J Pharmacol 1999, 127(5):1111-1118.
39. Pique J.M., Whittle B.J., Esplugues J.V. The vasodilator role of endogenous nitric oxide in the rat gastric microcirculation. Eur J Pharmacol 1989, 174(2-3):293-296.
40. Pique J.M., Esplugues J.V., Whittle B.J. Endogenous nitric oxide as a mediator of gastric mucosal vasodilatation during acid secretion. Gastroenterology 1992, 102(1):168-174.
41. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991, 88(11):4651-4655.
42. Wallace J.L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997, 112(3):1000-1016.
43. Salvemini D., Misko T.P., Masferrer J.L., Seibert K., Currie M.G., Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993, 90(15):7240-7244.
44. Khattab M.M., Gad M.Z., Abdallah D. Protective role of nitric oxide in indomethacin-induced gastric ulceration by a mechanism independent of gastric acid secretion. Pharmacol Res 2001, 43(5):463-467.
45. Lazaratos S., Kashimura H., Nakahara A., Fukutomi H., Osuga T., Goto K. l-Arginine and endogenous nitric oxide protect the gastric mucosa from endothelin-1-induced gastric ulcers in rats. J Gastroenterol 1995, 30(5):578-584.
46. Jimenez D., Martin M.J., Pozo D., Alarcon C., Esteban J., Bruseghini L., et al. Mechanisms involved in protection afforded by l-arginine in ibuprofen-induced gastric damage: role of nitric oxide and prostaglandins. Dig Dis Sci 2002, 47(1):44-53.
47. Konturek S.J., Brzozowski T., Majka J., Pytko Polonczyk J., Stachura J. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 1993, 239(1-3):215-217.
48. Hogaboam C.M., Jacobson K., Collins S.M., Blennerhassett M.G. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995, 268(4 Pt 1):G673-G684.
49. Yamamoto O., Okada Y., Okabe S. Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci 1984, 29(5):394-401.
50. Brzozowski T., Konturek S.J., Drozdowicz D., Dembinski A., Stachura J. Healing of chronic gastric ulcerations by l-arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Digestion 1995, 56(6):463-471.
51. Schwentker A., Vodovotz Y., Weller R., Billiar T.R. Nitric oxide and wound repair: role of cytokines?. Nitric Oxide 2002, 7(1):1-10.
52. Seifter E., Rettura G., Barbul A., Levenson S.M. Arginine: an essential amino acid for injured rats. Surgery 1978, 84(2):224-230.
53. Kirk S.J., Hurson M., Regan M.C., Holt D.R., Wasserkrug H.L., Barbul A. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993, 114(2):155-159. [Discussion 160].
54. Arbss M.A., Ferrando J.M., Vidal J., Quiles M.T., Huguet P., Castells J., et al. Early effects of exogenous arginine after the implantation of prosthetic material into the rat abdominal wall. Life Sci 2000, 67(20):2493-2512.
55. Albina J.E., Mills C.D., Henry W.L., Caldwell M.D. Temporal expression of different pathways of l-arginine metabolism in healing wounds. J Immunol 1990, 144(10):3877-3880.
56. Shi H.P., Efron D.T., Most D., Tantry U.S., Barbul A. Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout mice. Surgery 2000, 128(2):374-378.
57. Angele M.K., Nitsch S.M., Hatz R.A., Angele P., Hernandez Richter T., Wichmann M.W., et al. l-Arginine: a unique amino acid for improving depressed wound immune function following hemorrhage. Eur Surg Res 2002, 34(1-2):53-60.
58. Chen X., Li Y., Cai X., Xu W., Lu S., Shi J. Dose-effect of dietary l-arginine supplementation on burn wound healing in rats. Chin Med J (Engl) 1999, 112(9):828-831.
59. Yu Y.M., Ryan C.M., Castillo L., Lu X.M., Beaumier L., Tompkins R.G., et al. Arginine and ornithine kinetics in severely burned patients: increased rate of arginine disposal. Am J Physiol Endocrinol Metab 2001, 280(3):E509-E517.
60. Pieper G.M., Siebeneich W., Dondlinger L.A. Short-term oral administration of l-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol 1996, 317(2-3):317-320.
61. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88(10):1201-1203.
62. Giugliano D., Marfella R., Verrazzo G., Acampora R., Nappo F., Ziccardi P., et al. l-Arginine for testing endothelium-dependent vascular functions in health and disease. Am J Physiol 1997, 273(3 Pt 1):E606-E612.
63. Wascher T.C., Graier W.F., Dittrich P., Hussain M.A., Bahadori B., Wallner S., et al. Effects of low-dose l-arginine on insulin-mediated vasodilatation and insulin sensitivity. Eur J Clin Invest 1997, 27(8):690-695.
64. Lubec B., Hayn M., Kitzmuller E., Vierhapper H., Lubec G. l-Arginine reduces lipid peroxidation in patients with diabetes mellitus. Free Radic Biol Med 1997, 22(1-2):355-357.
65. Piatti P.M., Monti L.D., Valsecchi G., Magni F., Setola E., Marchesi F., et al. Long-term oral l-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care 2001, 24(5):875-880.
66. Schmidt H.H., Warner T.D., Ishii K., Sheng H., Murad F. Insulin secretion from pancreatic B cells caused by l-arginine-derived nitrogen oxides. Science 1992, 255(5045):721-723.
67. Thams P., Capito K. l-Arginine stimulation of glucose-induced insulin secretion through membrane depolarization and independent of nitric oxide. Eur J Endocrinol 1999, 140(1):87-93.
68. Bohme G.A., Bon C., Stutzmann J.M., Doble A., Blanchard J.C. Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol 1991, 199(3):379-381.
69. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993, 329(27):2002-2012.
70. Chapman P.F., Atkins C.M., Allen M.T., Haley J.E., Steinmetz J.E. Inhibition of nitric oxide synthesis impairs two different forms of learning. Neuroreport 1992, 3(7):567-570.
71. Ohtsuka Y., Nakaya J. Effect of oral administration of l-arginine on senile dementia. Am J Med 2000, 108(5):439.
72. Yi J., Horky L.L., Friedlich A.L., Shi Y., Rogers J.T., Huang X. l-Arginine and Alzheimer's disase. Int J Clin Exp Pathol 2009, 2(3):211-238.
73. Campbell B.I., La Bounty P.M., Roberts M. The ergogenic potential of arginine. J Int Soc Sports Nutr 2004, 1(2):35-38.
74. Gremion G., Pahud P., Gobelet C. Aspartate d'arginine et activite musculaire. Partie II [Arginine aspartate and muscular activity. II]. Schweiz Z Sportmed 1989, 37(4):241-246.
75. Angeli G., De Barros T.L., De Barros D.F.L., Lima M. Investigação dos efeitos da suplementação oral de arginina no aumento de força e massa muscular [Investigation of the effects of oral supplementation of arginine in the increase of muscular strength and mass]. Rev Bras Med Esporte 2007, 13(2):129-132.
76. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., et al. l-Arginine decreases inflammation and modulates the nuclear factor-κB/matrix metalloproteinase cascade in Mdx muscle fibers. Am J Pathol 2008, 172(6):1509-1519.
77. Chaubourt E., Fossier P., Baux G., Leprince C., Israel M., De La Porte S. Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis 1999, 6(6):499-507.
78. Fossel E.T. Improvement of temperature and flow in feet of subjects with diabetes with use of a transdermal preparation of l-arginine: a pilot study. Diabetes Care 2004, 27(1):284-285.
79. Klahr S. Can l-arginine manipulation reduce renal disease?. Semin Nephrol 1999, 19(3):304-309.
80. Park K.G., Hayes P.D., Garlick P.J., Sewell H., Eremin O. Stimulation of lymphocyte natural cytotoxicity by l-arginine. Lancet 1991, 337(8742):645-646.
81. Gupta V., Gupta A., Saggu S., Divekar H.M., Grover S.K., Kumar R. Anti-stress and adaptogenic activity of l-arginine supplementation. Evid Based Compl Altern Med 2005, 2(1):93-97.
82. Collier S.R., Casey D.P., Kanaley J.A. Growth hormone responses to varying doses of oral arginine. Growth Horm IGF Res 2005, 15(2):136-139.
83. Boger R.H., Bode Boger S.M., Mugge A., Kienke S., Brandes R., Dwenger A., et al. Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995, 117(2):273-284.
84. Grasemann H., Kurtz F., Ratjen F. Inhaled l-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 174(2):208-212.
85. Hendler S.S., Rorvik D. l-Arginine. PDR for nutritional supplements 2001, 248-254. Thomson Healthcare. 1st ed. S.S. Hendler, D. Rorvik (Eds.).